1. In Vivo
  2. >>Global Vision

The US: To Go, or Not to Go?

 
• By Melanie Senior

Whether or not European biotechs should establish operations in the US may seem like a no brainer: it's the biggest drugs market, with more potential partners, better funding, more promising exits for investors and a more experienced management pool than Europe. But getting there-and getting noticed-isn't easy. And since most executives agree that going to the US half-heartedly isn't worthwhile, Europe's biotechs need to think hard about when and whether they're ready to go. For a minority, setting up in the US may not be the right solution-for now.

There was little surprise when UK-based Shire PLC in May 2004 announced the establishment of its R&D headquarters and US commercial headquarters in Pennsylvania. "We need to address reality: 70% of our revenues come from the US," says CEO Matt Emmens, a US citizen who joined Shire in March 2003 from Merck KGAA . Other European-headquartered groups have made the same decision: Warner Chilcott PLC and Elan Pharmaceuticals recently sold off their UK and European businesses respectively; Galen changed its name to that of its US subsidiary, Warner Chilcott PLC , as a result [See Deal][See Deal].

For marketing-focused groups without the resources to go truly international, a US move makes sense: one approval accesses a population...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

The Rise In China Deals: How International Biopharma Is Turning To China For Innovation

 
• By Joseph Haas, Mary Jo Laffler, and Nancy Pham

The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

More from In Vivo

Too Big To Refill? Pharma’s Race To Replace $300bn In Expiring Revenues

 
• By Daniel Chancellor

An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.

Beyond Cebranopadol: Tris Pharma’s 25-Year Legacy In Drug Delivery Innovation

 
• By David Wild

Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.

Beyond Data Sharing: How Biopharma Is Rewriting The Rules Of Collaboration

 
• By David Wild

Pharmaceutical companies are creating collaborative AI platforms that simulate drug trials, accelerate discovery and democratize access to proprietary datasets.